Drugs in development · updated 11 November 2026
Abraxane: clinical trials and development status
As of 11 November 2026 Abraxane is in 12 active clinical trials (recruiting or ongoing, phases I–III) for 7 diseases. The most advanced phase is III.
Authorisation
- EU yes, since 11 Jan 2008 (EMA)
- Italy yes (EU authorisation)
- Germany yes (EU authorisation)
- US no (FDA)
Sources: EMA, AIFA register (open data), FDA. For Germany only the EU centralised authorisation is shown: the national BfArM register is not one of our sources.
Map of sites in Europe with recruitment status, every trial and an email when something changes. Full access free until 31 March 2027, no card needed.
What it is
A Cremophor EL-free, albumin-stabilized nanoparticle formulation of the natural taxane paclitaxel with antineoplastic activity. Paclitaxel binds to and stabilizes microtubules, preventing their depolymerization and so inhibiting cellular motility, mitosis, and replication. This formulation solubilizes paclitaxel without the use of the solvent Cremophor, thereby permitting the administration of larger doses of paclitaxel while avoiding the toxic effects associated with Cremophor.
Diseases studied
For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov.
| Disease | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| Pancreatic neoplasm | II | 2 | NCT04589234 |
| Biliary tract neoplasm | I–II | 1 | NCT05482893 |
| Colorectal neoplasm | I–II | 1 | NCT05482893 |
| Non-small-cell lung carcinoma | II | 1 | NCT06745882 |
| Triple-negative breast neoplasm | II | 1 | NCT07394387 |
| Metastasis | I | 2 | NCT05631899 |
| Lymphoma | I | 1 | NCT05631886 |
Sites in Europe
24 sites of the active trials in 5 European countries, 0 recruiting.
- Germany10
- Hungary4
- Poland4
- Bulgaria3
- United Kingdom3
Sites declared by the sponsors on ClinicalTrials.gov; region worked out by Phuturdex from the geographic point. The list of sites with city and recruitment status is in the app. See the sites →
Everything on Abraxane
In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.
Open in Phuturdex →Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 11 November 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, refers to the United States and is a Phuturdex calculation described on the Method page, not official data: the drug may already be marketed in other countries.